Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CPRX | US
0
0%
Healthcare
Drug Manufacturers-Specialty & Generic
30/06/2024
04/10/2024
20.00
20.09
20.23
19.93
Catalyst Pharmaceuticals Inc. a commercial-stage biopharmaceutical company focuses on developing and commercializing therapies for people with rare debilitating chronic neuromuscular and neurological diseases in the United States. It offers Firdapse an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals Inc. was founded in 2002 and is based in Coral Gables Florida.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Midcap (2B - 10B USD)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
24.5%1 month
28.9%3 months
41.0%6 months
37.4%34.93
9.62
3.81
0.01
0.00
15.92
4.49
-
122.45M
2.37B
2.37B
-
44.21
-
23.20
13.85
6.20
6.19
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.31
Range1M
2.67
Range3M
6.70
Rel. volume
0.54
Price X volume
10.96M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Amphastar Pharmaceuticals Inc | AMPH | Drug Manufacturers-Specialty & Generic | 46.72 | 2.29B | 0.47% | 15.24 | 87.00% |
PAR Technology Corporation | PAR | Drug Manufacturers-Specialty & Generic | 52.65 | 1.91B | 6.00% | n/a | 65.19% |
Harrow Health Inc | HROW | Drug Manufacturers-Specialty & Generic | 50.37 | 1.79B | 9.79% | n/a | 331.16% |
Supernus Pharmaceuticals Inc | SUPN | Drug Manufacturers-Specialty & Generic | 32.02 | 1.76B | -0.44% | 341.67 | 4.18% |
Tilray Inc | TLRY | Drug Manufacturers-Specialty & Generic | 1.69 | 1.42B | 0.60% | n/a | 11.25% |
Collegium Pharmaceutical Inc | COLL | Drug Manufacturers-Specialty & Generic | 41.86 | 1.35B | 6.76% | 14.38 | 258.31% |
OPKO Health Inc | OPK | Drug Manufacturers-Specialty & Generic | 1.49 | 1.03B | -1.97% | n/a | 19.31% |
Evolus Inc | EOLS | Drug Manufacturers-Specialty & Generic | 16.34 | 1.03B | -4.67% | n/a | 656.27% |
PetIQ Inc | PETQ | Drug Manufacturers-Specialty & Generic | 30.87 | 923.02M | 0.13% | 83.11 | 178.54% |
Phibro Animal Health Corporation | PAHC | Drug Manufacturers-Specialty & Generic | 21.31 | 863.13M | -2.07% | 367.83 | 204.74% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Albany International Corp | AIN | Textile Manufacturing | 77.72 | 2.43B | -10.58% | 24.91 | 38.97% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 15.92 | 17.21 | Par |
Ent. to Revenue | 4.49 | 334.38 | Cheaper |
PE Ratio | 34.93 | 26.92 | Expensive |
Price to Book | 3.81 | 12.15 | Cheaper |
Dividend Yield | - | 2.77 | - |
Std. Deviation (3M) | 40.96 | 68.34 | Lower Risk |
Debt to Equity | 0.01 | -1.00 | Expensive |
Debt to Assets | 0.00 | 0.48 | Cheaper |
Market Cap | 2.37B | 5.31B | Emerging |